Skip to main content
Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

A Study of IMO-2125 in Combination With Ipilimumab in Subjects With Melanoma (ILLUMINATE-301)

Research Question:
What is the effect of ipilimumab with and without intratumoral IMO-2125 in subjects with advanced melanoma who had confirmed disease progression while on nivolumab or pembrolizumab?

Basic Study Information

Purpose:
A Phase 3 global, multi-center, open-label comparison of ipilimumab with and without intratumoral IMO-2125 in subjects with advanced melanoma who had confirmed disease progression while on nivolumab or pembrolizumab

Location: University of Rochester Medical Center
Study Reference #: IMEL18087

Lead Researcher (Principal Investigator)

Lead Researcher: Deepak Sahasrabudhe, MD

Study Contact Information

Study Coordinator: Park Bogan
Phone: (585) 276-4415
Email: Park_Bogan@URMC.Rochester.edu

Additional Study Details

Return to Search